This is probably why we won’t see a cap raise. I think prior to the new proteomics data it may have been more likely, however with the multiple new indications possible and with a 9 month preclin/clin parallel program for the FDA and a MS P2 trial in lieu, I think ANP MD will have taken the partnership route to fund these different pipelines. M
We shall see soon, fingers crossed.
This is probably why we won’t see a cap raise. I think prior to...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
-0.001(1.30%) |
Mkt cap ! $68.51M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.6¢ | $15.61K | 200K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 110000 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 67730 | 2 |
View Market Depth
| Last trade - 12.51pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
-0.001 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 14800 | ||
| Last updated 15.52pm 06/05/2024 ? | |||||
| PER (ASX) Chart |